CN104906389B - 治疗糖尿病周围神经病变的中药 - Google Patents
治疗糖尿病周围神经病变的中药 Download PDFInfo
- Publication number
- CN104906389B CN104906389B CN201510298260.6A CN201510298260A CN104906389B CN 104906389 B CN104906389 B CN 104906389B CN 201510298260 A CN201510298260 A CN 201510298260A CN 104906389 B CN104906389 B CN 104906389B
- Authority
- CN
- China
- Prior art keywords
- parts
- blood
- chinese medicine
- root
- chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 34
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 15
- 230000007170 pathology Effects 0.000 title claims abstract description 14
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims abstract description 16
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000021286 stilbenes Nutrition 0.000 claims abstract description 16
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 241000545744 Hirudinea Species 0.000 claims abstract description 11
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 11
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 11
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 11
- 241001165494 Rhodiola Species 0.000 claims abstract description 11
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 10
- 240000004638 Dendrobium nobile Species 0.000 claims abstract description 10
- 241000521581 Millettia Species 0.000 claims abstract description 10
- 240000000249 Morus alba Species 0.000 claims abstract description 10
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 10
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 9
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 abstract description 44
- 239000008280 blood Substances 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 25
- 210000004185 liver Anatomy 0.000 abstract description 16
- 210000003734 kidney Anatomy 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 14
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 210000002569 neuron Anatomy 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 3
- 201000001119 neuropathy Diseases 0.000 abstract description 3
- 230000007823 neuropathy Effects 0.000 abstract description 3
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 3
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000036770 blood supply Effects 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000000686 essence Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002398 materia medica Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 4
- 235000007672 methylcobalamin Nutrition 0.000 description 4
- 239000011585 methylcobalamin Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960005321 mecobalamin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 230000007830 nerve conduction Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010067502 Decreased vibratory sense Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000214032 Hedysarum Species 0.000 description 1
- 241000266851 Hedysarum polybotrys Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124344 antianaemic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
- 229950010170 epalrestat Drugs 0.000 description 1
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000029761 vertebral disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗糖尿病周围神经病变的中药,它是由下列重量份的原料制成:红芪20‑30份、红景天3—6份、黄精10—20份、生地黄15—20份、桑椹15—20份、当归10—20份、太子参10—15份、枸杞10—20份、三七6—10份、石斛10—20份、葛根10—15份、鸡血藤15—20份、威灵仙10—20份、地龙6—15份和水蛭1‑3份。本发明中药具有补益肝肾、滋养精血、化瘀通脉的功用。可改善糖尿病作为神经病变患者的微血管循环,提高神经细胞血液供应,纠正神经细胞缺血缺氧的病理状态,从而减轻临床症状。本发明中药经临床大量运用高效、安全,未见明显毒副作用。
Description
技术领域
本发明属于中药领域,具体涉及一种治疗糖尿病周围神经病变的中药。
背景技术
糖尿病性周围神经病变(DPN)是指在排除其它原因的情况下,糖尿病患者出现与周围神经功能障碍相关的症状或(和)体征。远端对称性多发性神经病变是DPN最常见的类型。病情隐匿,进展缓慢,主要症状为四肢末端麻木感、刺痛、感觉异常,通常呈手套或袜套样分布,多从下肢开始,呈长度依耐性,夜间加重。体格检查示足部皮肤色泽黯淡,汗毛稀少,皮温较低;痛温觉、振动觉减退或缺失,踝反射正常或仅轻度减弱,运动功能基本完好。是糖尿病常见的微血管并发症,是糖尿病患者致残的主要原因之一。
根据流行病学调查显示,我国糖尿病患病率急剧上升,在过去20年中上升了4倍,年龄≧20岁以上人群的糖尿病患病率高达 9.7% ,以此推算目前中国有近1亿成年人患有糖尿病,中国已经成为世界上糖尿病患者最多的国家。糖尿病病史10年的病人发生周围神经病变者可达60%以上。
糖尿病患者由于长期高血糖状态导致一系列代谢紊乱,干扰了神经组织的能量代谢,使其结构和功能发生改变。主要表现为:(1)多元醇代谢通路活性增多。长期高血糖状态使山梨醇在细胞内大量积聚,造成神经组织对肌醇摄取减少,最终使酶活性下降,使神经细胞肿胀、变性,生理功能降低,传导速度减慢,节段性脱髓鞘和轴突消失,感觉神经损伤先于运动神经。(2)蛋白质糖基化使神经细胞结构和功能受到损害。高浓度葡萄糖可使神经组织内蛋白质发生糖基化,轴突的逆行运输出现障碍,干扰神经细胞蛋白质的合成,导致轴突变性、萎缩,最终形成神经细胞结构和功能改变,神经传导障碍。(3)糖尿病患者在高糖刺激性可导致微血管结构异常,表现微血管内皮细胞增生,基底膜增厚,从而引起末梢神经缺血、缺氧导致神经营养障碍和变性。
糖尿病周围神经病变属中医学“脉痹”、“血痹”、“络病”范畴, 糖尿病周围神经病变多发于40岁以上、病程10年左右的患者,根据患者临床症状及用药疗效,我们认为该病的主要病机是:肝肾亏虚、精血耗损、脉络瘀阻。
现代医学对该病的主要措施有控制血糖、调整代谢等,常用静滴硫辛酸、依帕司他片(唐林)、胰岛素、甲基维生素B12等治疗,临床效果欠佳。
发明内容
本发明的目的是提供一种治疗糖尿病周围神经病变的中药。
本发明技术方案如下:一种治疗糖尿病周围神经病变的中药,它是由下列重量份的原料制成:红芪20-30份、红景天3—6 份、黄精10—20份、生地黄15—20份、桑椹15—20份、当归10—20份、太子参10 —15份、枸杞10—20份、三七6—10份、石斛10—20份、葛根10—15 份、鸡血藤15—20份、威灵仙10—20份、地龙6—15份和水蛭1-3 份。
优选地,各原料的重量份配比如下、红芪25份、红景天5份、黄精10份、生地黄20份、桑椹15份、当归15份、太子参10份、枸杞15份、三七10份、石斛10份、葛根15份、鸡血藤15份、威灵仙15份、地龙10份和水蛭2份。
本发明中药可按中药药剂学制备工艺和辅料,根据原方配伍比例制备成中药颗粒剂或胶囊、口服液。
本发明药物选取优质道地中药材,红芪以甘肃省宕昌县、岷县产的为佳。红景天以产于西藏者佳。当归以甘肃省岷县产地为佳。
红芪为豆科植物多序岩黄芪的根,为黄芪的一个亚种,是黄芪中的上品,仅产于甘肃的岷县、武都、宕昌等地,因其皮色红润故称红芪。自古与黄芪通用 ,因为其产量稀少,药性纯正,自古以来大多征作贡用,只在宫廷御方上出现。红芪为甘肃的道地药材,早在《神农本草经》上就有记载,应用历史十分悠久。味甘,温。归肺、脾经。具有补气固表,利尿托毒,敛疮生肌的功效,用于治疗气虚乏力,血虚萎黄,内热消渴,慢性肾炎蛋白尿,糖尿病等疾病。红芪主要成分包括多糖,氨基酸,黄酮,生物碱等。红芪主要活性成分红芪多糖(HPS)能提高超氧化物歧化酶(SOD)活性,从而起到增强免疫力、抗衰老、增强淋巴因子活化杀伤细胞(LAK)对肿瘤细胞的杀伤和多种生物效应,可调整血糖。国内学者研究表明:红芪在增强脾细胞增殖能力、提高T-SOD活性,降低衰老细胞数方面优于黄芪。
红景天生长在高原地区,应用历史悠久,具有扶正固体、补气养血、滋阴益肺的神奇功效,历代藏医将其视为“吉祥三宝”。具有:抗脑缺氧、抗疲劳、活血止血、清肺止咳、化淤消肿、解热退烧、滋补元气、降糖降脂等多种功效,且无毒、无害,长期服用对人体有很好的保健作用 。
黄精味性甘,平。归脾、肺、肾经。具有补气养阴,健脾,润肺,益肾作用。《日华子本草》:“补五劳七伤,助筋骨,生肌,耐寒暑,益脾胃,润心肺”。 《本草纲目》:“补诸虚……填精髓”。 现代研究证实:黄精能提高机体免疫功能和促进DNA、RNA及蛋白质的合成,促进淋巴细胞转化作用;能降血脂及减轻冠状动脉粥样硬化程度;对肾上腺素引起的血糖过高呈显著抑制作用;还有抑制肾上腺皮质的作用和抗衰老作用。
生地黄性味甘、苦,寒。归心、肝、肾经。 具有清热凉血,养阴生津的功效。《神农本草经》:“主折跌绝筋,伤中,逐血痹,填骨髓,长肌肉,作汤除寒热积聚,除痹。生者尤良。”《珍珠囊》:“凉血,生血,补肾水真阴。
桑椹味性味甘、酸,寒。归肝、肾经。具有 滋阴补血,生津润燥的功效。《新修本草》:“主消渴”。《滇南本草》:“益肾脏而固精,久服黑发明目”。
当归性味 甘、辛,温。归肝、心、脾经。具有补血调经,活血止痛,润肠通便的作用。《日华子本草》:“主治一切风,一切血,补一切劳,破恶血,养新血及主癥癖。”现代药理研究证实:当归浸膏有显著扩张离体豚鼠冠脉作用,增加冠脉血流量。麻醉犬静注本品心率无明显改变,冠脉阻力和总外周阻力下降,冠脉血流量显著增加,心肌氧耗量显著下降,心排出量和心搏指数有增加趋势。当归中性油对实验性心肌缺血亦有明显保护作用。当归及其阿魏酸钠有明显的抗血栓作用。当归水浸液给小鼠口服能显著促进血红蛋白及红细胞的生成。
太子参性味甘、微苦、平。归脾、肺经。具有 补气健脾,生津润肺。本品能补脾肺之气,兼能养阴生津,其性略偏寒凉,属补气药中的清补之品。现代药理研究证实太子参对淋巴细胞有明显的刺激作用。
枸杞子性味 甘,平。归肝、肾经。具有 滋补肝肾,益精明目的作用。《本草经集注》:“补益精气,强盛阴道”。《药性论》:“补益精,诸不足,易颜色,变白,明目……令人长寿”。 现代研究证实:枸杞子对免疫有促进作用,同时具有免疫调节作用;可提高血睾酮水平,起强壮作用;对造血功能有促进作用;对正常健康人也有显著升白细胞作用;还有抗衰老、抗突变、抗肿瘤、降血脂、保肝及抗脂肪肝、降血糖、降血压作用。
三七,性味甘、微苦,温。归肝、胃经。具有化瘀止血,活血定痛,补虚强壮的作用,《本草求真》:“三七,世人仅知功能止血住痛,殊不知痛因血瘀则痛作,血因敷散则血止。三七气味苦温,能于血分化其血瘀。” 现代研究证实:本品能够缩短出血和凝血时间,具有抗血小板聚集及溶栓作用;能够促进多功能造血干细胞的增殖,具有造血作用;能够降低心肌耗氧量和氧利用率,扩张脑血管,增强脑血管流量;能够提高体液免疫功能,具有镇痛、抗炎、抗衰老等作用。
石斛性味甘,微寒。归胃、肾经。具有益胃生津,滋阴清热的作用。《神农本草经》:“主伤中,除痹,下气,补五脏虚劳羸瘦,强阴,久服厚肠胃”。《本草纲目拾遗》:“清胃,除虚热,生津,已劳损”。《本草再新》:“清胃火,除心中烦渴,疗肾经虚热”。
葛根性味甘、辛,凉。归脾、胃经。《神农本草经》:“主消渴,身大热,呕吐,诸痹,起阴气,解诸毒。” 现代药理研究:葛根具有降血糖作用。
鸡血藤性味苦、微甘,温。归肝、肾经。具有行血补血,调经,舒筋活络。《本草纲目拾遗》:“其藤最活血,暖腰膝,已风瘫。”;“壮筋骨,已酸痛,和酒服……治老人气血虚弱,手足麻木,瘫痪等证。”。《现代实用中药》:“为强壮性之补血药,适用于贫血性之神经麻痹症,如肢体及腰膝疼痛,麻木不仁等。又有活血镇痛之效。”
威灵仙性味辛、咸,温。归膀胱经。本品辛散温通,性猛善走,通行十二经,既能袪风湿,又能通经络而止痛,为治风湿痹痛要药。 并能消痰逐饮,用于痰饮、噎膈、痞积。《本草汇言》:“大抵此剂宣行五脏,通利经络,其性好走,亦可横行直往。追逐风湿邪气,荡除痰涎冷积,神功特奏。”《药品化义》:“灵仙,其猛急,善走而不守,宣通十二经络。主治风、湿、痰壅滞经络中,致成痛风走注,骨节疼痛,或肿,或麻木。”
地龙性味咸,寒。归肝、脾、膀胱经。本品性走窜,善于通行经络,止痛,适用于多种原因导致的经络阻滞、血脉不畅,肢节不利之症。
水蛭性味咸、苦,平。有小毒。归肝经。《神农本草经》:”主逐恶血,瘀血,月闭,破血逐瘀,无子,利水道。”。现代研究药理作用:水蛭水煎剂有强抗凝血作用,能显著延长纤维蛋白的凝聚时间,水蛭提取物、水蛭素对血小板聚集有明显的抑制作用,抑制大鼠体内血栓形成,对弥漫性血管内凝血有很好的治疗作用。水蛭煎剂能改善血液流变学。能降血脂,消退动脉粥样硬化斑块,增加心肌营养性血流量。
该发明治疗糖尿病周围神经病的中药复合物以红芪、红景天、生地黄、黄精补益肝肾气血为君药,太子参、枸杞、当归、桑椹、石斛滋养脏腑精血为臣药;葛根、鸡血藤、三七、地龙、水蛭、活血化瘀,通络止痛为佐药;威灵仙通行十二经,既能袪风湿,又能通经络而止痛,并能消痰逐饮为使药。上述药物配方严谨,切准糖尿病周围神经病变病机:肝肾亏虚、精血耗损、脉络瘀阻。针对主要病机共同发挥补益肝肾、滋养精血、化瘀通脉的功用。通过大量临床资料验证,该方临床疗效确切,未见明显不良反应及毒副作用。本人发明的佛手神饮通过补益肝肾、滋养精血、化瘀通脉,可改善糖尿病作为神经病变患者的微血管循环,提高神经细胞血液供应,纠正神经细胞缺血缺氧的病理状态,从而减轻临床症状。
本发明可以按中药常规制备技术制成颗粒剂、胶囊、口服液等剂型。经临床大量运用高效、安全,未见明显毒副作用。该制剂的治疗效果明显高于国内相关文献的临床疗效。可缩短住院日程,减轻患者经济负担,可节省了医疗资源,具有良好的经济效益和较好的社会效益。
具体实施方式
实施例1
配方:红芪25g,红景天5 g,黄精10 g,生地黄20g,桑椹15g,当归15 g,太子参10g,枸杞15 g,三七10g,石斛10g,葛根15 g,鸡血藤15 g,威灵仙15 g,地龙10g,水蛭2g。本实施例配方效果最佳。
工艺:可按中药药剂学制备工艺和辅料制备成胶囊,每天服3次。
实施例2
红芪20g,红景天3 g,黄精15 g,生地黄15g,桑椹15g,当归10g,太子参10 g,枸杞10g,三七6g,石斛10g,葛根10g,鸡血藤15 g,威灵仙10g,地龙6g,水蛭1 g。
煎服方法:每日1剂,水煎2次混合共600ml,餐后半小时每次口服200 mL,每天服3次。
实施例3
红芪30g,红景天6g,黄精20g,生地黄20g,桑椹20g,当归20g,太子参15g,枸杞20g,三七10g,石斛20g,葛根15 g,鸡血藤20g,威灵仙20g,地龙15g,水蛭3 g。
煎服方法:每日1剂,水煎2次混合共600ml,餐后半小时每次口服200 mL,每天服3次。
《相关实验资料》
1、选取病例标准:选取本发明人所在宕昌县人民医院内科2009年6月至2014年3月门诊及住院的糖尿病周围神经病变患者132例,按1:1比例以随即双盲法分为治疗组和对照组。治疗组66例,对照组66例,二组病例在性别、年龄、病程及体征方面无显著差异(P>0.05),具有可比性。
2、诊断标准:糖尿病周围神经病诊断标准参照2009年中国医师协会内分泌代谢科医师分会组织撰写的《糖尿病周围神经病变临床诊疗规范》诊断。(1)明确的糖尿病病史;(2)在诊断糖尿病时或之后出现的神经病变;(3)临床症状和体征与DPN的表现相符;(4)以下5项检查中如果有2项或2项以上异常则诊断为DPN:温度觉异常;尼龙丝检查,足部感觉减退或消失;振动觉异常;踝反射消失; 神经传导速度(NCV)有2项或2项以上减慢。排除其它病变(腰椎病、脑梗死、格林巴利综合症、严重动静脉血管病变、药物中毒等)。
3、治疗方法:两组患者均给予糖尿病饮食、宣教,适量运动。根据患者血压、血脂加用降糖、降压及他汀类降脂药。治疗组给予本发明中药口服液,每次口服200 mL,每天服3次。对照组不服用中药。15天为1疗程。两组综合治疗2个疗程后进行疗效评价。
4、疗效判定标准采用多伦多(Toronto)临床评分系统进行评分。以疗效指数作为判定标准,疗效指数=(治疗前积分-治疗后积分)/治疗前积分×100%。临床痊愈:积分减少≧95%;显效:积分减少≧70%;有效:积分减少≧30%;无效:积分减少﹤30%。
5、治疗结果见表1:痊愈率3.03%,显效率63.63%,有效率90.90%,无效9.09%。
6、统计学方法:结果以标准差表示,采用t检验比较,以P<0.05为有统计学意义。
7、结论 通过大量临床资料验证,本发明中药具有高效、安全,节约医疗成本,简便易行、低毒副作用等优点。具有很好的开发价值及使用前景。
典型病例:
1、马xx,男,57岁,宕昌县居,糖尿病病史7年,出现麻木刺痛病史3年,经多种方法治疗疗效不佳。在我院住院期间,经综合治疗,服用本发明所述药物一个疗程后,症状基本消失。
2、杨xx,女,61岁,患糖尿病病史9年,患糖尿病周围神经病变2年,一直使用胰岛素控制血糖,长期服用甲钴胺,硫辛酸等药物,临床效果不佳。在调整血糖、控制血压的基础上,服用本发明所述药物一个疗程后,症状基本减轻,继续服用1个疗程后症状基本消失。
3、车xx,男,58岁,患糖尿病病史15年,患糖尿病周围神经病变3年,双下肢冰凉,长期穿棉袜不缓解,经针灸理疗效果也不理想。一直使用胰岛素控制血糖,长期服用甲钴胺,硫辛酸等药物,临床效果不佳。在我院住院期间,经综合治疗,服用本发明所述药物一个疗程后,症状缓解,按原方比例将本发明中药改为胶囊剂长期服用,上述症状基本稳定。
4、罗xx,男,65岁,患糖尿病病史5年,患糖尿病周围神经病变5月,一直使用二甲双胍、格列喹佟控制血糖,长期服用甲钴胺,唐林等药物,症状时轻时重。在调整血糖、控制血压的基础上,服用本发明所述药物一个疗程后,症状明显减轻,继续服用1个疗程后症状基本消失。
Claims (2)
1.一种治疗糖尿病周围神经病变的中药,其特征在于它是由下列重量份的原料制成:红芪20-30份、红景天3—6 份、黄精10—20份、生地黄15—20份、桑椹15—20份、当归10—20份、太子参10 —15份、枸杞10—20份、三七6—10份、石斛10—20份、葛根10—15 份、鸡血藤15—20份、威灵仙10—20份、地龙6—15份和水蛭1-3 份。
2.根据权利要求1所述的治疗糖尿病周围神经病变的中药,其特征在于:各原料的重量份配比如下,红芪25份、红景天5份、黄精10份、生地黄20份、桑椹15份、当归15份、太子参10份、枸杞15份、三七10份、石斛10份、葛根15份、鸡血藤15份、威灵仙15份、地龙10份和水蛭2份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510298260.6A CN104906389B (zh) | 2015-06-03 | 2015-06-03 | 治疗糖尿病周围神经病变的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510298260.6A CN104906389B (zh) | 2015-06-03 | 2015-06-03 | 治疗糖尿病周围神经病变的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104906389A CN104906389A (zh) | 2015-09-16 |
CN104906389B true CN104906389B (zh) | 2018-04-17 |
Family
ID=54076105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510298260.6A Expired - Fee Related CN104906389B (zh) | 2015-06-03 | 2015-06-03 | 治疗糖尿病周围神经病变的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104906389B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513506A (zh) * | 2003-08-15 | 2004-07-21 | 关志国 | 治疗糖尿病周围神经病变的药物 |
CN1660263A (zh) * | 2004-12-13 | 2005-08-31 | 贵阳云岩西创药物科技开发有限公司 | 芪蛭降糖片及其制备方法 |
CN1742936A (zh) * | 2004-08-30 | 2006-03-08 | 北京阜康仁生物制药科技有限公司 | 一种治疗糖尿病的天然药物制剂及其制备方法 |
CN101584772A (zh) * | 2009-06-23 | 2009-11-25 | 方朝晖 | 一种治疗糖尿病周围神经病变的中药 |
KR101257578B1 (ko) * | 2010-12-24 | 2013-04-23 | 대전대학교 산학협력단 | 당뇨병성 말초 신경증 치료를 위한 한약재 조성물 |
CN104510806A (zh) * | 2013-10-07 | 2015-04-15 | 青岛联合创新技术服务平台有限公司 | 一种治疗糖尿病周围神经病变的中药组方 |
-
2015
- 2015-06-03 CN CN201510298260.6A patent/CN104906389B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1513506A (zh) * | 2003-08-15 | 2004-07-21 | 关志国 | 治疗糖尿病周围神经病变的药物 |
CN1742936A (zh) * | 2004-08-30 | 2006-03-08 | 北京阜康仁生物制药科技有限公司 | 一种治疗糖尿病的天然药物制剂及其制备方法 |
CN1660263A (zh) * | 2004-12-13 | 2005-08-31 | 贵阳云岩西创药物科技开发有限公司 | 芪蛭降糖片及其制备方法 |
CN101584772A (zh) * | 2009-06-23 | 2009-11-25 | 方朝晖 | 一种治疗糖尿病周围神经病变的中药 |
KR101257578B1 (ko) * | 2010-12-24 | 2013-04-23 | 대전대학교 산학협력단 | 당뇨병성 말초 신경증 치료를 위한 한약재 조성물 |
CN104510806A (zh) * | 2013-10-07 | 2015-04-15 | 青岛联合创新技术服务平台有限公司 | 一种治疗糖尿病周围神经病变的中药组方 |
Non-Patent Citations (6)
Title |
---|
中西医结合治疗糖尿病神经病变42例;林轶蓉;《山西中医》;20030630(第03期);第22页 * |
加味黄芪六一汤治疗糖尿病周围神经病变;刘斯尧;《浙江中西医结合杂志》;20070310(第03期);第193页 * |
益气活血通络汤治疗糖尿病周围神经病变58例;常宗范等;《实用中医内科杂志》;20010625(第02期);第17-18页 * |
糖尿病周围神经病变临证治疗50例;张红蕾;《光明中医》;20090920(第09期);第1694页 * |
补阳还五汤加减治疗糖尿病周围神经病变68例;华刚等;《光明中医》;20090820;第24卷(第08期);第1487-1488页 * |
降糖通脉汤治疗糖尿病周围神经病变50例;刘香春;《辽宁中医学院学报》;20010928;第03卷(第03期);第206页左栏"2治疗方法"、右栏倒数第1段和第207页左栏倒数第2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN104906389A (zh) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102988750B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN107693767A (zh) | 一种防治糖尿病足的外用中药组合物、其制备方法及应用 | |
CN103638250B (zh) | 一种治疗面神经麻痹的中药制剂及其制备方法 | |
CN1247231C (zh) | 一种产后补血保健药物及其制备方法和应用 | |
CN102846955A (zh) | 一种中药增高鞋垫 | |
CN102935185B (zh) | 一种用于治疗神经衰弱的丸剂及制备方法 | |
CN102824469B (zh) | 一种中药戒毒药物及其制备方法 | |
CN104825956A (zh) | 防治中风、康复筋骨关节的药 | |
CN104906389B (zh) | 治疗糖尿病周围神经病变的中药 | |
CN104623583A (zh) | 一种治疗虚寒腹痛的药物及其口服液制备方法 | |
CN103735643B (zh) | 治疗糖尿病周围神经病变的中药组合物 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN102406893A (zh) | 一种治疗银屑病的中成药 | |
CN104547642A (zh) | 一种治疗女性纤维肌痛综合征的中药组合物 | |
CN110507796A (zh) | 一种治疗多种疾病的中药配方 | |
CN103656488B (zh) | 一种治疗糖尿病并发糖尿病足的中药组合物 | |
CN101954030B (zh) | 一种治疗糖尿病的内服药物 | |
CN102068670B (zh) | 治疗高血脂症的中药组合物 | |
CN107029151A (zh) | 用于治疗心脾两虚型失眠的药物 | |
CN106138475A (zh) | 一种预防糖尿病皮肤病的浴足中药组合物 | |
CN105687436A (zh) | 用于治疗牛皮癣的外用中药膏剂及其制备方法 | |
CN104771603B (zh) | 一种改善唾液酸异常的中药口服药及制备方法 | |
CN104645244A (zh) | 一种治疗动脉硬化症的中药组合物 | |
CN101337050B (zh) | 一种治疗脑血管意外的中药组合物及其生产方法 | |
CN103272072B (zh) | 一种用于治疗银屑病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180417 |